Compare General Motors Company (GM) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Illumina, Inc. — how do they compare? General Motors Company trades at $89.08 (market cap $78.40B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: General Motors Company is far larger — about 2.7× Illumina, Inc.'s market cap, and General Motors Company pays a 0.81% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| GM | ILMN | |
|---|---|---|
Market Cap | $78.40B | $29.12B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $205.10 |
52-Week Low | $54.16 | $91.00 |
Enterprise Value | $181.38B | $30.48B |
Dividend Yield | 0.81% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
